Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Autoimmunity, infectious immunity, and atherosclerosis.

Matsuura E, Kobayashi K, Matsunami Y, Shen L, Quan N, Makarova M, Suchkov SV, Ayada K, Oguma K, Lopez LR.

J Clin Immunol. 2009 Nov;29(6):714-21. doi: 10.1007/s10875-009-9333-5. Review.

PMID:
19795194
2.

Immunogenic oxidized low-density lipoprotein/beta2-glycoprotein I complexes in the diagnostic management of atherosclerosis.

Lopez LR, Kobayashi K, Matsunami Y, Matsuura E.

Clin Rev Allergy Immunol. 2009 Aug;37(1):12-9. doi: 10.1007/s12016-008-8096-8. Review.

PMID:
18982458
3.

Atherosclerosis in autoimmune diseases.

Matsuura E, Kobayashi K, Lopez LR.

Curr Rheumatol Rep. 2009 Feb;11(1):61-9. Review.

PMID:
19171113
4.

OxLDL/beta2GPI-anti-oxLDL/beta2GPI complex and atherosclerosis in SLE patients.

Bassi N, Ghirardello A, Iaccarino L, Zampieri S, Rampudda ME, Atzeni F, Sarzi-Puttini P, Shoenfeld Y, Doria A.

Autoimmun Rev. 2007 Nov;7(1):52-58. doi: 10.1016/j.autrev.2007.06.003. Epub 2007 Jul 24. Review.

PMID:
17967726
5.

Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis.

Matsuura E, Kobayashi K, Tabuchi M, Lopez LR.

Prog Lipid Res. 2006 Nov;45(6):466-86. Epub 2006 May 30. Review.

PMID:
16790279
6.

The role of innate and adaptive immunity to oxidized low-density lipoprotein in the development of atherosclerosis.

Kobayashi K, Lopez LR, Shoenfeld Y, Matsuura E.

Ann N Y Acad Sci. 2005 Jun;1051:442-54. Review.

PMID:
16126986
7.

Proatherogenic oxidized low-density lipoprotein/β2-glycoprotein I complexes in arterial and venous disease.

Berger JS, Rockman CB, Guyer KE, Lopez LR.

J Immunol Res. 2014;2014:234316. doi: 10.1155/2014/234316. Epub 2014 Oct 28.

9.

Autoimmune-mediated atherothrombosis.

Matsuura E, Lopez LR.

Lupus. 2008 Oct;17(10):878-87. doi: 10.1177/0961203308093553. Review.

PMID:
18827052
11.

Oxidized LDL/beta2-glycoprotein I complexes: new aspects in atherosclerosis.

Matsuura E, Kobayashi K, Inoue K, Lopez LR, Shoenfeld Y.

Lupus. 2005;14(9):736-41. Review.

PMID:
16218478
12.
13.
14.

Atherogenic antiphospholipid antibodies in antiphospholipid syndrome.

Kobayashi K, Lopez LR, Matsuura E.

Ann N Y Acad Sci. 2007 Jun;1108:489-96. Review.

PMID:
17894014
15.

Atherosclerosis-related markers in systemic lupus erythematosus patients: the role of humoral immunity in enhanced atherogenesis.

George J, Harats D, Gilburd B, Levy Y, Langevitz P, Shoenfeld Y.

Lupus. 1999;8(3):220-6.

PMID:
10342715
17.

Recombinant domain V of β2-glycoprotein I inhibits the formation of atherogenic oxLDL/β2-glycoprotein I complexes.

Li J, Chi Y, Liu S, Wang L, Wang R, Han X, Matsuura E, Liu Q.

J Clin Immunol. 2014 Aug;34(6):669-76. doi: 10.1007/s10875-014-0063-y. Epub 2014 Jun 27.

PMID:
24970589
18.

β2-glycoprotein I and oxidative inflammation in early atherogenesis: a progression from innate to adaptive immunity?

Matsuura E, Lopez LR, Shoenfeld Y, Ames PR.

Autoimmun Rev. 2012 Dec;12(2):241-9. doi: 10.1016/j.autrev.2012.04.003. Epub 2012 Apr 27. Review.

PMID:
22569463
19.

The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis.

Tabuchi M, Inoue K, Usui-Kataoka H, Kobayashi K, Teramoto M, Takasugi K, Shikata K, Yamamura M, Ando K, Nishida K, Kasahara J, Kume N, Lopez LR, Mitsudo K, Nobuyoshi M, Yasuda T, Kita T, Makino H, Matsuura E.

J Lipid Res. 2007 Apr;48(4):768-81. Epub 2007 Jan 29.

20.

Intravenous immunoglobulin and atherosclerosis.

Matsuura E, Kobayashi K, Inoue K, Shoenfeld Y.

Clin Rev Allergy Immunol. 2005 Dec;29(3):311-9. Review.

PMID:
16391407

Supplemental Content

Support Center